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cuevas2, Nicola Salvarese3, Mariangela figini  4, Giulio fracasso  5 ✉, Laura De nardo6, 
Cristina Bolzati3, Antonio Rosato1,7,8 & Laura Meléndez-Alafort  1,8 ✉
The clinical translation of theranostic 177Lu-radiopharmaceuticals based on inhibitors of the prostate-
specific membrane antigen (PSMA) has demonstrated positive clinical responses in patients with 
advanced prostate cancer (PCa). However, challenges still remain, particularly regarding their 
pharmacokinetic and dosimetric properties. We developed a potential PSMA-immunotheranostic 
agent by conjugation of a single-chain variable fragment of the IgGD2B antibody (scFvD2B) to DOTA, 
to obtain a 177Lu-labelled agent with a better pharmacokinetic profile than those previously reported. 
The labelled conjugated 177Lu-scFvD2B was obtained in high yield and stability. In vitro, 177Lu-scFvD2B 
disclosed a higher binding and internalization in LNCaP (PSMA-positive) compared to PC3 (negative 
control) human PCa cells. In vivo studies in healthy nude mice revealed that 177Lu-scFvD2B present a 
favorable biokinetic profile, characterized by a rapid clearance from non-target tissues and minimal liver 
accumulation, but a slow wash-out from kidneys. Micro-SPECT/CT imaging of mice bearing pulmonary 
microtumors evidenced a slow uptake by LNCaP tumors, which steadily rose up to a maximum value 
of 3.6 SUV at 192 h. This high and prolonged tumor uptake suggests that 177Lu-scFvD2B has great 
potential in delivering ablative radiation doses to PSMA-expressing tumors, and warrants further 
studies to evaluate its preclinical therapeutic efficacy.
Background. Prostate cancer (PCa) is the second leading cause of cancer deaths for adult men in the Western 
world. Although radical prostatectomy and local radiotherapy are largely successful for patients with localized 
cancer, available treatments for metastatic PCa have demonstrated weak curative efficacy1. Consequently, new 
tools to improve the detection of recurrent PCa, and particularly to identify and treat distant metastases, are 
imperatively needed.
The prostate-specific membrane antigen (PSMA) is one of the most promising targets for the development of 
PCa theranostic agents. PSMA is overexpressed in 95% of prostate cancers and its expression levels progressively 
increase in high-grade tumors and in metastatic disease, up to 1,000 times more than in normal cells2. Among the 
several PSMA-targeting molecules that have been developed, the radiolabeled Glu-ureido-based PSMA inhibi-
tors are gaining much interest due to their high uptake by PSMA-positive cancer cells, and low background and 
excellent contrast in cancer imaging, even in small metastases3,4. Theranostic agents such as 177Lu-PSMA-617, 
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177Lu-PSMA-I&T and 177Lu-iPSMA have demonstrated their ability to efficiently target PSMA-expressing tum-
ors, with the consequent decrease of serum PSA levels in 30–60% of PCa patients5,6. However, the individual 
dosimetry calculation disclosed high absorbed doses in the lacrimal and salivary glands due to the high retention 
of 177Lu-PSMA-ligands7. As consequence, most 177Lu-labeled PSMA inhibitors are currently employed only as 
compassionate treatment for patients with end-stage metastatic castration-resistant PCa8.
Antibody-based constructs represent another strategy that has been pursued in order to develop 
PSMA-imaging or theranostic agents. To date, only the murine monoclonal antibody (mAb) 111In-capromab 
pendetide (ProstaScint®) has been approved by the Food and Drug Administration as a diagnostic agent for 
PCa. However, ProstaScint® binding sites are exposed only after apoptosis or necrosis processes9. Smith-Jones 
et. al. developed the humanized J591 mAb, which recognizes and binds to an extracellular epitope of PSMA with 
high affinity. Nonetheless, as a whole antibody it exhibits low tumor targeting with a maximum uptake at 6 days 
post-injection, and delayed clearance from non-target tissues9; these issues limit the use of J591 as a theranostic 
agent10. Recently, a new mAb against human PSMA (IgGD2B) was developed using conventional hybridoma 
technology11. 111In-IgGD2B has a higher tumor uptake than ProstaScint, but presents the same limitations due to 
its molecular size12. To circumvent this problem, single-chain variable fragments (scFv) of the D2B antibody have 
been produced13. Optical in vivo mouse imaging of fluorophore-labeled scFv (scFvD2B) evidenced high speci-
ficity and rapid accumulation in PSMA-positive tumors, with no apparent background13. Subsequently, recom-
binant 111In-NOTA-scFvD2B displayed some kidney uptake that was significantly reduced when scFvD2B was 
radiolabeled with I-13114. A GMP-grade 123I-labelled scFvD2B showed improved antigen-positive tumor uptake 
with a shorter circulatory half-life, but also an increased uptake in non-target tissues, such as the stomach and 
thyroid gland, due to the release of I-123 by a process of in vivo 123I-scFvD2B dehalogenation15.
Radiolabelled-antibodies with higher stability can be obtained using metal chelating agents, due to the signif-
icant reduction of the radioisotope release16. DOTA is one of the primary used chelators for radio-metals chem-
istry and has proved to be an excellent chelator for Lutetium. Actually, Lu-DOTA complexes show remarkable 
kinetic and thermodynamic stability, with no significant in vivo metal release even after long circulation times17.
In this study, scFvD2B was conjugated to DOTA and labeled with 177Lu (177Lu-scFvD2B) to assess stability, 
immunoreactivity, binding and internalization properties using PSMA-expressing cells. Additionally, biodistri-
bution studies were carried out in healthy and LNCaP tumor-bearing mice to establish 177Lu-scFvD2B pharma-
cokinetic profile, and to assess its potential as an immunotheranostic agent.
Methods
Cell lines. The human prostate cancer LNCaP and androgen-independent bone metastasis PC-3 cell lines 
were obtained from the American Type Culture Collection (ATCC). The cell subline PC-3-PIP, modified to 
express high levels of PSMA, was kindly provided by Dr W. Heston (Cleveland, USA).
Synthesis and characterization of the DOTA-scFvD2B conjugate. All chemicals were purchased 
from Sigma-Aldrich unless otherwise specified. DOTA (S-2-(4-benzyl-isothiocyanate)−1,4,7,10-tetra-azacyc
lododecane tetraacetic-acid) was purchased from Macrocyclics.
ScFvD2B (MW 27 kDa) was produced in an eukaryotic system (ExcellGene) and purified on protein 
L-sepharose column (GE Healthcare) as previously described13,15. To synthesize the DOTA-scFvD2B conjugate, 
a concentrated solution of scFvD2B (10 mg/mL) in 0.2 M sodium carbonate buffer (pH 9.5) was incubated with 
p-SCN-Bz-DOTA at 37 °C using 1:2, 1:3 1:4 and 1:5 scFv:DOTA molar ratios. The coupling reaction was quenched 
by adjusting the pH to 7.0 with 0.25 M ammonium acetate buffer, pH 5.518. In order to remove the DOTA excess, 
the conjugate was washed with 0.25 M ammonium acetate (pH 7.0), using a Vivaspin® centrifugal concentrator 
(MWCO 5 kDa; Sartorius). Matrix-assisted laser desorption ionization mass spectrosmetry (MALDI-MS) meas-
urements were performed on a REFLEX 4800 Plus MALDI TOF/TOF instrument (AB Sciex) to determine the 
number of DOTA per each scFvD2B molecule. Desalted solutions of scFvD2B and DOTA-scFvD2B were diluted 
to a volume ratio of 1:1 in sinapinic acid solution (10 mg/mL in 50:50 acetonitrile/water). Samples with a final 
concentration of 5 mg/mL were deposited on a metal MALDI target plate and analyzed. The average number of 
DOTA per scFvD2B was estimated dividing the mass difference between conjugated and unconjugated scFvD2B 
by the mass of DOTA (551 Da).
The affinity constant value (Kd) of the DOTA-scFvD2B conjugate was determined by flow cytometry using 
a BD FACSCanto II cytometer (Becton and Dickinson). PC-3-PIP and PC-3 cells were re-suspended in cold 
phosphate-buffered saline (PBS) solution with 0.2% of bovine serum albumin and serial dilutions of the samples 
were added. After a 1-hour incubation period in ice, cells were washed and stained with saturating amounts of 
Protein-L Biotin (Life Technologies) in PBS solution over ice for 30 min. Then, cells were washed again and stained 
with saturating amounts of fluorescein isothiocyanate labeled Avidin (Vector Laboratories). Cell-associated flu-
orescence was measured by flow cytometry; the percentage of positive cells and the mean fluorescence inten-
sity values were considered. For each sample, under both saturating conditions, the mean fluorescence intensity 
value was proportional to the number of PSMA sites; therefore, data was expressed as percent saturation of the 
total stainable PSMA sites. Blocking experiments were also performed on PSMA expressing LNCaP cells, using 
Fluorescein-5-isothiocyanate (FITC) labeled mAb D2B and increasing concentrations of scFvD2B or its DOTA 
derivative as described by Parker et al.19.
Radiolabeling of PSMA target agents. To establish the minimal amount of DOTA-scFvD2B necessary to 
obtain 177Lu-DOTA-scFvD2B (177Lu-scFvD2B) with a high radiochemical yield, 0.5 mL of 0.25 M sodium acetate 
buffer (pH 7.0), containing different concentrations of DOTA-scFvD2B (15, 30, 60 and 75 nmol), were incubated 
with 15 µL (from 100 to 370 MBq) of no-carrier-added 177LuCl3 (ITG) for 2 h at 37 °C. The radiochemical yield 
of 177Lu-scFvD2B was assessed at 1 and 2 h by high performance liquid chromatography (HPLC). Analyses were 
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carried out using a Waters instrument running Empower software with both radioactivity and UV-photodiode 
array in-line detectors, using a size-exclusion Zorbax GF-250 column (4.59 μm, 9 × 250 mm) from Agilent, and 
0.1 M phosphate buffer, pH 7.0, at a 1 mL/min flow rate as mobile phase.
For comparative purposes, 177Lu-iPSMA was obtained from the lyophilized kit (ININ-Mexico)20, while 
177Lu-PSMA-617 from DOTA-PSMA-617 purchased from ABX, and used as positive controls. Radiolabeled reac-
tions were carried out, by addition of 0.5 mL (100 MBq) of 177LuCl3 solution at pH 5 to the DOTA-conjugates and 
incubation for 30 min at 95 °C in a dry bath as described elsewhere21. The radiochemical yield was evaluated by 
instant thin layer chromatography in glass microfiber paper impregnated with a silica gel (ITLC-SG), using 10-cm 
strips of Whatman paper and a solution of NaCl 0.9% in 0.02 M HCl as mobile phase. In this system, the free 177Lu 
travels to the front (Rf = 9–10) and the 177Lu-PSMA conjugates remain close to the origin (Rf = 1-2).
Stability studies were performed by diluting 0.2 nmol of 177Lu-scFvD2B in 100 µL of phosphate buffer (0.1 M; 
pH 7.0) or human serum, and incubated for 192 h at 37 °C. 177Lu-scFvD2B stability was assessed at different time 
points using radio-HPLC method, as previously reported.
Cell binding and internalization. To assess the 177Lu-radiotracers cell uptake, a solution containing 1 × 
105 LNCaP or PC-3 cells diluted in 1 mL of fresh medium was added to a glass tube and incubated with 10 µL (2 
MBq and 120 pmol) of 177Lu-labeled scFvD2B, iPSMA or PSMA-617 at 37 °C for 1 h (in triplicate). Subsequently, 
cells were washed twice with PBS solution and counted in a gamma-counter. The internalized fraction of 
177Lu-PSMA conjugates was calculated after elimination of the membrane-bound radiotracer, by incubating cells 
with 1 mL of glycine buffer (pH 2.8) for 2 min, washing them with PBS and counting the cell pellet. Total uptake 
and internalization were expressed as moles of scFvD2B (pmol) in the cell pellet (105 cells) with regard to the total 
amount (pmol) of the scFvD2B added.
In vivo studies. Animal studies were performed according to national and international ethical regulations, 
for the handling of laboratory animals (Official Mexican Norm 062-ZOO-1999). This research was approved 
by the CICUAL-ININ Ethics Committee (Internal Committee of Care and Use of Laboratory Animals of the 
National Institute of Nuclear Research, Approval No. 02-2018).
Biodistribution and pharmacokinetic studies of 177Lu-scFvD2B in healthy mice were carried out by injection 
of 0.1 mL (3.7 MBq and 0.57 nmol) into the tail vein of 8-week-old nude male mice. Groups of animals (n = 3) 
were then sacrificed at 0.5, 3, 24 and 192 h post-injection. Selected organs (heart, lung, liver, pancreas, spleen and 
kidneys) and tissue samples (intestine, muscle, bone and blood) were dissected, weighed and measured with a 
NaI(Tl) crystal scintillation detector. The activity of the injected dose of 177Lu-scFvD2B solution was simultane-
ously measured in order to calculate the uptake as percentage of the injected dose per gram of tissue (%ID/g). 
Biodistribution data expressed as percentage of injected dose per organ (%ID/organ) was used as input for the 
CoKiMo spreadsheet software22 to obtain the organ time-activity curves. 177Lu-scFvD2B biological mean resi-
dence time (MRT) was computed by integration of the curve obtained for each organ. Finally, 177Lu-scFvD2B 
effective MRT was calculated by integration of the main organ activity curves, corrected by the physical decay of 
Lu-177.
A pulmonary microtumors mice model was used to assess the potential of 177Lu-scFvD2B uptake in tumors at 
micro-size level. Imaging studies were carried out inducing pulmonary microtumors in two groups of 8-week-old 
nude male mice (n = 3), by injection of 300,000 LNCaP or PC-3 cells (in 0.2 mL of phosphate-buffered saline) into 
the tail vein. A week later, tumor-bearing mice were injected with 177Lu-scFvD2B (0.1 mL; 3.7 MBq), and under 
2% isoflurane anesthesia, were placed in the animal-scanner (Albira, ONCOVISION, Spain). First, a computed 
tomography (CT) scan was achieved with 35 kV sure voltage and 700 µA to acquire an anatomical reference. 
Subsequently, single-photon-emission computed tomography (SPECT) scans were obtained at 0.5, 3, 6, 24, 48, 
72 and 192 h after intravenous (i.v.) administration, using a field of view of 60 mm, set at 208 keV (symmet-
ric 20% window). Then, images were obtained by dataset reconstruction using the Ordered Subset Expectation 
Maximization, OSEM, algorithm. The region of interest of the tumor, main organs and whole body were drawn 
for each time point. PMOD 3.8 (Technologies Ltd, Switzerland) software was used to obtain quantitative data 
from images, and the OsiriX MD (Pixmeo SARL, Switzerland) software was employed for 3D image reconstruc-
tion.These activity data, the weight of each mouse and the time of administration and acquisition (for decay cor-
rection), were used by the PMOD software to calculate the standardized uptake values (SUV) (see Supplementary 
Information Figs. S1–S7). Tumor SUVs were used to generate the tumor kinetic curves and to calculate the 
tumor/heart and tumor/muscle ratios. Finally, mice were sacrificed after the last scan (192 h); blood and selected 
organs were collected and measured in order to calculate the % ID/g of tissue. For comparative purposes and as a 
positive control, studies on mice bearing LNCaP pulmonary tumors treated with 177Lu-iPSMA were also carried 
out as described above.
Statistical analysis. The results are expressed as the mean ± standard deviation of the indicated deter-
minations numbers. In vitro cancer cell uptake and internalization of 177Lu-scFvD2B, 177Lu-iPSMA and 
177Lu-PSMA-617 were compared with GraphPad Prism software using two-way ANOVA test, p ≤ 0.05 was con-
sidered to be a significant difference.
Results
Synthesis of the DOTA-scFvD2B conjugate. The scFvD2B was conjugated to DOTA in 0.2 M carbonate 
buffer pH 9.5 with different scFv:DOTA molar ratios at 37 °C. MALDI-MS analyses of all DOTA-scFvD2B conju-
gates showed multi-peaked spectra in all cases. These data indicated that a heterogeneous number of DOTA was 
conjugated to each scFvD2B molecule. The highest number of DOTA conjugated to scFvD2B was obtained using 
a 1:5 (scFvD2B:DOTA) molar ratio. Under this condition, a minimal amount of unconjugated scFvD2B (peak 
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at 26,644) was found, and an average of 1.7 DOTA molecules per scFvD2B was estimated, considering the entire 
area of the peaks (Fig. 1A).
Binding assays on PSMA-transfected PC-3-PIP cells demonstrated that DOTA conjugation slightly reduced 
scFvD2B affinity for PSMA (Fig. 1B). The Kd for scFvD2B and DOTA-scFvD2B conjugate, obtained using 
a 1:5 molar ratio, were 19.1 ± 1.0 nM and 43.9 ± 1.7 nM (n = 3), respectively. The PC-3 cell line was used as a 
PSMA-negative control. Binding specificity for scFvD2B and DOTA-scFvD2B was confirmed by their negligible 
attachment to PSMA-negative PC-3 cells (Fig. 1B).
The binding specificity was also confirmed by blocking experiments on LNCaP cells analysed by flow cytom-
etry. Indeed, when a 500 molar excess of scFvD2B or its DOTA derivative were used, a shift to the left of the 
fluorescent peak was observed, which was due to a clearly reduction of mAb D2B-FITC binding to LNCaP cells 
(see Supplementary Fig. 8S ).
Radiolabeling and in vitro stability. HPLC analyses demonstrated that, to obtain 177Lu-scFvD2B 
with a radiochemical yield over 97% and molar activity up to 18 MBq/nmol, it is necessary to add at least 30 
nmol of DOTA-scFvD2B to 15 µL of 177LuCl3 and incubate for 1 h at 37 °C and pH 7. However, the amount 
of DOTA-conjugate can be reduced if the incubation time increases to 2 h (Fig. 2A). HPLC analyses of 
177Lu-scFvD2B after dilution in human serum or phosphate buffer confirmed its high stability. Radiochemical 
purity after dilution in both solutions was higher than 98% at 192 h (Fig. 2B). Radiochromatograms showed no 
presence of new peaks that indicate aggregation or breakdown of 177Lu-scFvD2B during the study period.
Radiochemical yield of both positive controls, 177Lu- iPSMA and 177Lu-PSMA-617, was higher than 98%.
Figure 1. (A) Overlapping of MALDI-MS spectra of the unconjugated scFvD2B (red line) and DOTA-
scFvD2B conjugate obtained, using a 1:5 (scFvD2B:DOTA) molar ratio (black line). (B) Binding affinity studies 
conducted by flow cytometry on the PSMA-positive PC-3-PIP cells (dots) and PSMA-negative PC-3 cells 
(triangles).
Figure 2. (A) Radiochemical yield for increasing amounts of DOTA-scFvD2B, incubated at 37 °C for 1 and 2 h. 
(B) Size-exclusion HPLC radiochromatograms of 177Lu-scFvD2B obtained with a molar activity of 18 MBq/
nmol without dilution (black line) and after 24 and 192 h dilution in 0.1 M phosphate buffer at pH 7.0 (red and 
blue lines respectively).
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Cell binding and internalization. Transduced PC3-PIP cells present much higher PSMA expression levels 
than LNCaP cells23. In spite of this, the in vitro and in vivo studies with 177Lu-scFvD2B were carried out using 
LNCaP cells, as in such cell line PSMA is expressed endogeneously and physiologically thus recapitulating better 
the real clinical setting and at the same time allowing to compare our results with the data reported in literature. 
In vitro studies showed a statistically significant higher cell uptake and internalization of 177Lu-scFvD2B than 
177Lu-PSMA-617 and 177Lu-iPSMA in LNCaP cells (Fig. 3). The most remarkable difference between the antibody 
fragment and Glu-ureido based PSMA inhibitors was in cell internalization, which was at least 4 times higher for 
177Lu-scFvD2B. This data confirmed the high in vitro affinity of 177Lu-scFvD2B for PSMA. Non-specific uptake of 
radiolabeled conjugate by PC-3 cells also seems to be greater than 177Lu-PSMA-617 and 177Lu-iPSMA, even if a 
non-statistically significant difference was found.
Biodistribution studies of 177Lu-scFvD2B. Ex-vivo biodistribution studies were performed on healthy 
mice to determine the exact tissue uptake and MRT of 177Lu-scFvD2B in each organ. Figure 4 displays the 
177Lu-scFvD2B biodistribution data at different time points post-injection, expressed as %ID/g. These results 
demonstrated that 177Lu-scFvD2B presents a favorable biokinetic profile, characterized by a rapid clearance from 
non-target tissues, as well as minimal liver accumulation. Biokinetic curves obtained from the biodistribution 
data, expressed as %ID/organ, demonstrated the rapid blood clearance, but also showed that kidney is the organ 
with the highest uptake and slowest wash-out (Fig. 5). This outcome could be explained by the predominant elim-
ination of the scFv fragments through the renal-urinary pathway with a possible reabsorption in the proximal 
tubules24.
Values of 177Lu-scFvD2B biological MRT in most organs was lower than 1 hour, except for the liver and kidney, 
with 2.02 and 5.76 h, respectively. However, when the physical decay of lutetium-177 was considered, the effective 
MRT was significantly reduced in all cases (Table 1).
Figure 3. (A) Cell uptake and (B) internalization of 177Lu-labeled scFvD2B, 177Lu-PSMA-617 and 177Lu-
iPSMA by PSMA-negative PC-3 and PSMA-positive LNCaP cells, after 2 h of incubation with 2 MBq of 177Lu-
radiotracers (16 MBq/nmol) at 37 °C. Bars represent the average value ± SD of one experiment performed in 
triplicate, **p < 0.005 and ****p < 0.0001, two-way ANOVA.
Figure 4. Biodistribution data (decay-corrected) up to 192 h after injection of 3.7 MBq (6.5 MBq/nmol) of 
177Lu-scFvD2B in healthy nude male mice, and expressed as %ID/g. Bars represent the average value ± SD 
obtained from each group of mice (n = 3).
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SPECT/CT imaging studies of 177Lu-scFvD2B. SPECT/CT imaging of mice bearing LNCaP pulmo-
nary microtumors after injection of 37 MBq (6.5 MBq/nmol) dose of 177Lu-radiotracers clearly proved that 
177Lu-iPSMA disclosed the fastest tumor uptake (Fig. 6A). Three hours after administration, the 177Lu-iPSMA 
tumor SUV was 2.3 and gradually increased, reaching its maximum concentration by 24 h post-injection, fol-
lowed by a gradual clearance (Fig. 6B). In contrast, 177Lu-scFvD2B uptake in LNCaP tumors was slower, since at 
3 h after injection the SUV was 1.6, but steadily rose up to a maximum value of 3.6 at 192 h (Fig. 6B). However, no 
statistically significant differences were found in lung weight and no appreciable morphological changes between 
healthy and tumor-bearing mice.
Looking at the tumor kinetic curves, it is clear that the area under the curve was larger for 177Lu-scFvD2B 
than for 177Lu-iPSMA, which means that more disintegrations and higher radiation absorbed doses are expected 
Figure 5. (A) 177Lu-scFvD2B blood clearance. (B) Biokinetic curves of non-target organs with rapid clearance. 
(C) Biokinetic curves of non-target organs with slower clearance.
Organ
177Lu-scFvD2B MRT
Biologic (h) Effective (h)
Blood 0.536 0.372
Heart 0.032 0.003
Lungs 0.541 0.265
Liver 2.023 1.417
Pancreas 0.069 0.011
Spleen 0.067 0.008
Kidneys 5.763 3.782
Table 1. Calculated 177Lu-scFvD2B biological and effective Mean Residence Times (MRT) in the main organs.
Figure 6. (A) SPECT/CT images of mice bearing LNCaP lung microtumors collected at different time points 
after injection of 37 MBq dose of 177Lu-iPSMA (upper panels) and 177Lu-scFvD2B (lower panels). Images are 
representative of one out three mice selected for each group. (B) 177Lu-scFvD2B and 177Lu-iPSMA tumor kinetic 
curves obtained from the pulmonary microtumors data. CT and SPECT single images, as well as axial and 
sagittal sections displaying the microtumor locations of each mouse, are shown in Supplementary Information 
(see Figs. S9–S32).
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to occur in tumors treated with 177Lu-scFvD2B. In addition, no radioactivity in neck or head was observed that 
could indicate 177Lu-scFvD2B retention in salivary glands. The PC-3 tumor activity curve shows lower uptake of 
177Lu-scFvD2B with faster elimination (Fig. 6B).
177Lu-scFvD2B organ uptake at 192 h post-injection in mice bearing LNCaP or PC-3 tumors are reported as 
%ID/g in Table 2. The concentration of 177Lu-scFvD2B in the main source organs was calculated using the SPECT 
imaging at 192 h, and was congruous with the %ID/g of organs obtained at the same time from the ex-vivo biodis-
tribution studies in tumor-bearing mice.
Mice bearing micro-pulmonary tumors also showed a high kidney uptake, which slowly decreased over 
time, similar to what observed in healthy mice (Fig. 4). Kidney uptake of mice bearing PC-3 tumors was higher 
than for those bearing LNCaP tumors, although a non-statistically significant difference was found 192 h after 
177Lu-scFvD2B injection.
The micro-pulmonary tumors (2 mm3) model was useful to predict the 177Lu-scFvD2B uptake in tumors at 
micro-size level. However, the tumor dimensions do not allow tissue dissection for exact determinations of the 
tumor uptake as %ID/g; therefore, the tumor/heart and tumor/muscle ratios were calculated using organ SUVs 
obtained at 192 h for LNCaP and PC-3 tumors (Table 2). Both tumor/heart and tumor/muscle ratios show to be 
20 fold higher in PSMA-positive tumors with respect the negative ones.
Discussion
Based on the encouraging results obtained with 123I-scFvD2B for early diagnosis of PCa15, this study examined the 
feasibility of using scFvD2B to obtain a theranostic agent for PSMA-expressing tumors. The method for the labe-
ling of the scFvD2B fragment with 177Lu was described, and tumor cell uptake and internalization was studied. 
A healthy mice model was used to determine 177Lu-scFvD2B biodistribution and pharmacokinetic properties, as 
well as a pulmonary microtumors mouse model to compare tumor kinetics of 177Lu-scFvD2B and 177Lu-iPSMA.
177Lu-scFvD2B was obtained with a high radiochemical purity (>97%). Stability studies demon-
strated that 177Lu-scFvD2B disclosed a much higher stability in solution than 117Lu-PSMA-617 and the 
albumin-binder-conjugates reported as 177Lu-PSMA-ALB-56 and 177Lu-PSMA-ALB-0225,26. Binding on PC-3-PIP 
cells performed by flow cytometry, demonstrated a scFvD2B Kd (19.1 ± 1.0 nM) slightly above the Kd reported by 
Frigerio et. al. (8.6 nM) using surface plasmon resonance (Biacore 2000)14. DOTA conjugation of the scFvD2B 
fragment, employing the 1:5 (scFvD2B:DOTA) molar ratio, reduced its affinity to 43.9 ± 1.7 nM. Nonetheless, 
177Lu-scFvD2B showed a statistically-significant higher uptake for LNCaP cells than 177Lu-PSMA-617 and 
177Lu-iPSMA, endowed with lower Kd values (6.33 ± 2.69 and 7.34 ± 2.97 nM, respectively)21. The higher 
177Lu-scFvD2B tumor uptake could be explained by its greater internalization, which allows a higher concentra-
tion of radioactivity inside the cells.
Biodistribution studies showed that 177Lu-scFvD2B presents a blood clearance quite similar to that reported 
for 111In-scFvD2B14. Both radiometal-chelate complexes showed 0.19% ID/g in blood at 24 h after injec-
tion. This value is considerably lower than that reported for whole antibodies (from 12 to 25%ID/g)27,28, or 
for the albumin-binder-conjugated 177Lu-PSMA-617 as the 177Lu-HTK0116923, 177Lu-PSMA-ALB-5625 and 
177Lu-PSMA-ALB-0226 (from 0.45 to 2.10%ID/g at 24 h), but higher than the 177Lu-PSMA-617 blood uptake (0.12 
and 0.00%ID/g at 4 and 24 h, respectively)23. However, blood concentration of the most-promising albumin con-
jugates decreased quite fast 24 h after injection, and blood concentration values at 192 h were quite similar to 
those of 177Lu-scFvD2B (see Supplementary Table 1 S). Consequently, 177Lu-scFvD2B showed two advantages: 
higher internalization by PSMA-expressing cells than 177Lu-labeled urea derivatives, and lower radiation dose 
delivered to the non-target tissues, compared to 177Lu-anti-PSMA antibodies.
Biodistribution of 177Lu-scFvD2B and 111In-NOTA-scFvD2B derivatives showed significant differences in liver 
uptake values. 111In-scFvD2B hepatic uptake at 3 and 24 h (19.48 ± 13.91% and 22.89 ± 12.42% ID/g, respec-
tively)14 was 20-fold greater than that for 177Lu-scFvD2B (0.95 ± 0.04% ID/g at 3 h and 0.60 ± 0.03% ID/g at 24 h). 
This result can be explained by the fact that authors used NOTA, which is not the best chelating agent for In-11129. 
Therefore, In-111 can be released from the complex, forming insoluble metal hydroxides that non-specifically 
Organ
LNCaP tumors 
(n = 3)
PC-3 tumors 
(n = 3)
Blood 0.04 ± 0.01 0.05 ± 0.00
Heart 0.03 ± 0.00 0.07 ± 0.01
Liver 0.29 ± 0.01 0.28 ± 0.03
Pancreas 0.08 ± 0.01 0.07 ± 0.01
Spleen 0.25 ± 0.04 0.22 ± 0.03
Kidneys 2.63 ± 0.22 2.99 ± 0.23
Intestine 0.12 ± 0.04 0.19 ± 0.06
Muscles 0.01 ± 0.00 0.02 ± 0.00
Bones 0.51 ± 0.06 0.39 ± 0.04
Tumor/heart* 50.55 ± 1.13 2.24 ± 0.21
Tumor/muscle* 34.51 ± 7.10 1.59 ± 0.09
Table 2. Uptake of 177Lu-scFvD2B in nude male mice bearing LNCaP or PC-3 pulmonary microtumors at 192 h 
post-injection. Values are %ID/g, expressed as mean ± SD. *Tumor-to-organ ratios were calculated from the 
SUVs obtained at 192 h.
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bind to high-molecular-weight biomolecules, which are then metabolized by liver and spleen. In contrast, the 
DOTA chelator contributes to the great stability of 177Lu-scFvD2B, resulting in a low liver and spleen uptake. In 
fact, the calculated 177Lu-scFvD2B liver effective MRT (1.42 h) in mice was in the same order of magnitude as the 
177Lu-PSMA-617 effective MRT (4.46 ± 1.72 h) in humans, as reported by Khawar et al.30.
It has been reported that murine PSMA, a 752-aminoacids glycoprotein with 91% similarity to the human 
PSMA 750-aminoacid sequence, is highly expressed in mouse kidneys31. Therefore, the high kidney uptake 
observed in mice upon administration of urea-based PSMA therapeutic agents might be due to the binding to the 
PSMA mouse isoform, likely following the interaction with the enzymatic site of PSMA proteins. Nonetheless, 
this would not likely represent a constrain for clinical use, since only minimal expression of PSMA has been 
found in human kidneys21,23,32. On the other hand, the high kidney accumulation of both 177Lu-scFvD2B and 
111In-DTPA-D2B fragments28 does not likely rely on specific or non-specific binding to murine PSMA, as the 
administration of an excess of unlabeled antibody fragment did not modify kidney uptake. Indeed, kidney 
uptake is a common feature of radiolabeled scFv fragments that are endowed with a molecular weight lower 
than the renal clearance threshold (i.e. 60 kDa), thus leading to both renal filtration and partial re-absorption in 
the proximal tubules. In this regard, such limits could be partially overcome by amino acid infusions33 or other 
approaches24. The low kidney accumulation of 131I-scFvD2B reported by Frigerio et al.14 could be partly ascribable 
to a phenomenon of quick dehalogenation of the construct after administration34, leading to loss of the signal at 
the kidney tissue, and the release of 131I16 that in turn concentrates in the thyroid gland and stomach as showed 
by the SPECT/CT images15. Overall, in-depth biodistribution analyses in humans are mandatory to assess the 
real renal uptake before draining a conclusion about the potential application of scFv moieties for therapeutic 
purposes.
177Lu-scFvD2B SPECT/CT imaging in mice bearing pulmonary microtumors displayed a slow tumor uptake, 
which was maintained for 192 h, and a rapid kidney uptake that decreased over time. Similar outcomes were 
reported by Kou et. al. using the 177Lu-HTK0116923. Biokinetic curves demonstrated that the LNCaP tumor 
uptake and retention of 177Lu-scFvD2B was higher than for 177Lu-iPSMA. Similar results were found by Kou et. 
al., when compared to 177Lu-PSMA-617 with 177Lu-HTK0116923. These results are most likely consequences of 
different factors, such as the higher stability, slower blood clearance and higher tumor cell internalization of the 
radiotracers with higher molecular weight, as well as their metabolism in tumor cells, related to the retention of 
radioactivity in tumors27. Based on these results, it can be deduced that 177Lu-scFvD2B could supply a higher 
radiation dose to PSMA-positive tumors than 177Lu-iPSMA and could therefore be a better theranostic agent. 
Consequently, dosimetrics studies should be carried out even though the clinical translation is certainly more 
expensive for a labeled antibody fragment than urea derivatives. In addition, the scFvD2B ligand prepared in 
this research could also be conjugated to deferoxamine for the labelling with zirconium-89 for PET imaging and 
possible routine use of the 89Zr-/177Lu-scFvD2B as theranostic companion.
Conclusions
The 177Lu-scFvD2B fragment was obtained with a high radiochemical yield and purity and showed specific rec-
ognition for PSMA-expressing tumors in vivo and in vitro. In addition, the high 177Lu-scFvD2B stability and 
internalization trigger a high and prolonged tumor uptake, providing to this agent a great potential in delivering 
ablative radiation doses to PSMA-expressing tumors. However, further studies must be carried out in order to 
evaluate the dosimetry and therapeutic efficacy of 177Lu-scFvD2B.
Data availability
All data generated or analysed during this study are included in this published article and its Supplementary 
Information files.
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